The official advocacy organization for pharmacist women in the United States
Pharmacist Moms Group™
45,000+ Members
Over 6 Million posts, comments and reactions in 2020
60,000+ Followers on social media platforms
The Largest Community of Women Pharmacists in the US
Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.
While we may not be able to control what happens to us, we can ALWAYS control how we respond. Working on self-awareness and self-improvement will certainly create positive habits to help you when you are stuck.
Read on to learn more about Jennifer’s path to pharmacy ownership, and to learn how COVID-19 and the Oregon wildfires have impacted her business.
Miss America 2020, Camille Schrier, has been a proud, self-described “science nerd” for as long as she can remember. We caught up with Camille to get a student’s perspective on the future of the profession.
The blood test offers a promising new approach to identify patients who are at high risk for recurrence and guide precision treatment strategies.
Pharmacist-led MTM services can deliver measurable clinical and financial value while advancing patient-centered care.
Oncology Pharmacists Connect 2026 emphasized the pharmacist’s role in translating rapidly evolving evidence into patient-centered, operationally feasible cancer care.
The panelists examined how early recognition of TD allows providers to optimize antipsychotic therapy and minimize or eliminate anticholinergic medications before patients progress to higher-burden treatment options such as clozapine.
Tynosynovial giant cell tumor (TGCT) is a rare, locally aggressive condition that significantly impacts patient quality of life and function, yet many patients wait years for diagnosis and may endure multiple surgeries with higher recurrence rates. In this series, Sasha Watson, PharmD (Sylvester Comprehensive Cancer Center) and Alexis Tandyk, PharmD, BCOP (University of Colorado Health), discuss CSF1R inhibitors, the targeted approach transforming TGCT management. They review the pathophysiology and disease burden context, clinical trial evidence from MOTION and ENLIVEN, strategies for differentiating between CSF1R agents, proactive toxicity management frameworks, and practical steps for building a systematic, pharmacist-led TGCT care model.
In this episode, 'Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in Myeloma,' the oncology pharmacists explore the following question: 1. Transition planning needs to begin before the first dose is administered, not after step-up dosing is complete. What does that pre-treatment planning look like at your institution?
Official Media Partner
.png)
Official CE Partner
Founder of Women Pharmacist Day
